Verano Holdings (VRNO) Non-Current Debt (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Non-Current Debt of $394.9 million for Q1 2026, down 2.2% year-over-year from $403.8 million in Q1 2025, and up 0.78% quarter-over-quarter from $391.9 million in Q4 2025.
Verano Holdings (VRNO) Non-Current Debt (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Non-Current Debt for 6 consecutive years, with $394.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 2.2% year-over-year to $394.9 million; the TTM figure through Mar 2026 stood at $394.9 million (down 2.2% YoY), while the FY2025 annual figure was $391.9 million, down 5.31% from the prior year.
- Non-Current Debt grew to $394.9 million in Q1 2026 per VRNO's latest filing, from $391.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $420.4 million in Q2 2023 and bottomed at $143.7 million in Q2 2022.
- Historically, Non-Current Debt has averaged $386.4 million across 5 years, with a median of $396.8 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt surged 192.44% — and 2024, when it slipped 5.85%.
- Verano Holdings' Non-Current Debt stood at $388.5 million in 2022, then increased by 1.31% to $393.6 million in 2023, then advanced by 5.13% to $413.8 million in 2024, then decreased by 5.31% to $391.9 million in 2025, then advanced by 0.78% to $394.9 million in 2026.
- Business Quant data shows VRNO's Non-Current Debt at $394.9 million in Q1 2026, $391.9 million in Q4 2025, and $397.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 130.00 Mn |
| 10 | Verano Holdings | 441.74 Mn | 356.55 Mn | 99.70 Mn | 392.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 392.61 Mn |
| Mar 31, 2026 | 394.95 Mn |
| Dec 31, 2025 | 391.88 Mn |
| Sep 30, 2025 | 397.82 Mn |
| Jun 30, 2025 | 403.27 Mn |
| Mar 31, 2025 | 403.83 Mn |
| Dec 31, 2024 | 413.85 Mn |
| Sep 30, 2024 | 420.15 Mn |
| Jun 30, 2024 | 395.78 Mn |
| Mar 31, 2024 | 391.27 Mn |
| Dec 31, 2023 | 393.64 Mn |
| Sep 30, 2023 | 415.48 Mn |
| Jun 30, 2023 | 420.38 Mn |
| Mar 31, 2023 | 415.34 Mn |
| Dec 31, 2022 | 388.54 Mn |
| Sep 30, 2022 | 392.14 Mn |
| Jun 30, 2022 | 143.75 Mn |
| Dec 31, 2021 | 289.93 Mn |